Contribute Try STAT+ Today

Good morning, all, I hope everyone is off to a good start. Ed is out today, so it’s Casey Ross here, coming to you from a farm in Northeast Ohio. The chickens have laid nine eggs so far and the tallest of the short people are off to school. Meanwhile, buzzards are circling blue skies over the cornfield, a telltale sign of predation in the shadows of the stalks. But on this Thursday, we prefer to think of it as confirmation that the cycle of nature is working as intended. And as we sip a nutty Costa Rican brew, with the musty flavors of another distant farm, we see that the news cycle is also churning at a rapid clip. Here are a few nuggets to chew as you continue your day.

Scientists from the Food and Drug Administration have expressed skepticism about the need for additional doses of Pfizer’s (PFE) Covid-19 vaccine for all recipients, STAT reports. The assessments of agency staffers, included in documents released Wednesday, sets up a high-stakes debate among outside experts Friday. They will be charged with sorting through conflicting data and lines of reasoning in a battle whose outcome will determine whether additional doses are needed, by whom, and when.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment